Evidence map›Paper›PMID 35958230›Full record

ArticleFrontiers in chemistry2022

Synthesis and Discovery of Ligustrazine-Heterocycle Derivatives as Antitumor Agents.

Shitang Ma, Ning Zhang, Jiafu Hou, Shijuan Liu, Jiawen Wang, Baowei Lu, Fucheng Zhu, Peipei Wei, Ge Hong, Tianjun Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shitang MaCollege of Biological and Pharmaceutical Engineering, West Anhui University, Lu'an, China.
Ning ZhangCollege of Life and Health, Anhui Science and Technology University, Fengyang, China.
Jiafu HouMudanjiang Medical University, Mudanjiang, China.
Shijuan LiuMudanjiang Medical University, Mudanjiang, China.
Jiawen WangInstitute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Biomedical Material, Tianjin, China.
Baowei LuCollege of Biological and Pharmaceutical Engineering, West Anhui University, Lu'an, China.
Fucheng ZhuCollege of Biological and Pharmaceutical Engineering, West Anhui University, Lu'an, China.
Peipei WeiCollege of Biological and Pharmaceutical Engineering, West Anhui University, Lu'an, China.
Ge HongInstitute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Biomedical Material, Tianjin, China.
Tianjun LiuInstitute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Biomedical Material, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ligustrazine (TMP) is a natural pyrazine alkaloid extracted from the roots of Ligusticum Chuanxiong Hort, which has the potential as an antitumor agent. A series of 33 ligustrazine-heterocycle (TMPH) derivatives were designed, synthesized, and investigated via antitumor screening assays, molecular docking analysis, and prediction of drug-like properties. TMP was attached to other heterocyclic derivatives by an 8-12 methylene alkyl chain as a linker to obtain 33 TMPH derivatives. The structures were confirmed by

Indexed as

antitumorapoptosisligustrazine–heterocyclic (TMPH) derivativesproliferationtriple-negative breast cancer

Identifiers

PMID35958230
PMCPMC9358002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.